Association of HLA match on nonrelapse and overall mortality
| . | . | Nonrelapse mortality* . | Overall mortality† . | ||
|---|---|---|---|---|---|
| . | Number . | HR (95% CI) . | P value . | HR (95% CI) . | P value . |
| Overall HLA match | |||||
| 1-allele mismatched vs matched | 226 vs 117 | 2.79 (1.46-5.34) | .002 | 1.31 (0.95-1.81) | .09 |
| 2-allele mismatched vs matched | 410 vs 117 | 2.69 (1.44-5.03) | .002 | 1.20 (0.89-1.63) | .23 |
| 3-allele mismatched vs matched | 464 vs 117 | 3.60 (1.94-6.69) | <.0001 | 1.36 (1.01-1.84) | .04 |
| 4-allele mismatched vs matched | 254 vs 117 | 3.48 (1.84-6.66) | .0001 | 1.15 (0.83-1.58) | .39 |
| 5-allele mismatched vs matched | 85 vs 117 | 4.61 (2.31-9.17) | <.0001 | 1.63 (1.12-2.39) | .01 |
| 3- to 4-allele vs 1- to 2-allele mismatched | 718 vs 637 | 1.31 (1.07-1.59) | .01 | 1.03 (0.89-1.19) | .69 |
| 5- vs 1- to 2-allele mismatched | 85 vs 637 | 1.69 (1.16-2.46) | .006 | 1.32 (0.99-1.76) | .06 |
| 5- vs 3- to 4-allele mismatched | 85 vs 718 | 1.29 (0.90-1.86) | .16 | 1.28 (0.96-1.70) | .09 |
| Single allele mismatch | |||||
| HLA-A mismatched vs matched | 117 vs 117 | 3.05 (1.52-6.14) | .002 | 1.27 (0.88-1.83) | .19 |
| HLA-B mismatched vs matched | 31 vs 117 | 1.26 (0.35-4.55) | .72 | 1.06 (0.75-1.97) | .77 |
| HLA-C mismatched vs matched | 40 vs 117 | 3.04 (1.28-7.20) | .01 | 1.41 (0.86-2.31) | .17 |
| HLA-DRB1 mismatched vs matched | 66 vs 117 | 2.93 (1.38-6.25) | .005 | 1.31 (0.96-1.78) | .17 |
| . | . | Nonrelapse mortality* . | Overall mortality† . | ||
|---|---|---|---|---|---|
| . | Number . | HR (95% CI) . | P value . | HR (95% CI) . | P value . |
| Overall HLA match | |||||
| 1-allele mismatched vs matched | 226 vs 117 | 2.79 (1.46-5.34) | .002 | 1.31 (0.95-1.81) | .09 |
| 2-allele mismatched vs matched | 410 vs 117 | 2.69 (1.44-5.03) | .002 | 1.20 (0.89-1.63) | .23 |
| 3-allele mismatched vs matched | 464 vs 117 | 3.60 (1.94-6.69) | <.0001 | 1.36 (1.01-1.84) | .04 |
| 4-allele mismatched vs matched | 254 vs 117 | 3.48 (1.84-6.66) | .0001 | 1.15 (0.83-1.58) | .39 |
| 5-allele mismatched vs matched | 85 vs 117 | 4.61 (2.31-9.17) | <.0001 | 1.63 (1.12-2.39) | .01 |
| 3- to 4-allele vs 1- to 2-allele mismatched | 718 vs 637 | 1.31 (1.07-1.59) | .01 | 1.03 (0.89-1.19) | .69 |
| 5- vs 1- to 2-allele mismatched | 85 vs 637 | 1.69 (1.16-2.46) | .006 | 1.32 (0.99-1.76) | .06 |
| 5- vs 3- to 4-allele mismatched | 85 vs 718 | 1.29 (0.90-1.86) | .16 | 1.28 (0.96-1.70) | .09 |
| Single allele mismatch | |||||
| HLA-A mismatched vs matched | 117 vs 117 | 3.05 (1.52-6.14) | .002 | 1.27 (0.88-1.83) | .19 |
| HLA-B mismatched vs matched | 31 vs 117 | 1.26 (0.35-4.55) | .72 | 1.06 (0.75-1.97) | .77 |
| HLA-C mismatched vs matched | 40 vs 117 | 3.04 (1.28-7.20) | .01 | 1.41 (0.86-2.31) | .17 |
| HLA-DRB1 mismatched vs matched | 66 vs 117 | 2.93 (1.38-6.25) | .005 | 1.31 (0.96-1.78) | .17 |
Adjusted for patient age, disease, disease status, precryopreserved TNC, and transplant period: nonrelapse mortality risks were higher for patients >16 years compared with younger patients (HR 1.60, 95% CI 1.26-2.03, P < .001); acute lymphoblastic leukemia (HR 1.35, 95% CI 1.09-1.69, P = .007) compared with acute myeloid leukemia; risks were not significantly different for myelodysplastic syndrome (HR 1.23, 95% CI 0.88-1.72, P = .26) compared with acute myeloid leukemia; for those transplanted in relapse/refractory anemia with excess blasts (HR 1.68, 95% CI 1.28-2.20, P < .001) but not those transplanted in second complete remission (HR 0.97, 95% CI 0.77-1.22, P = .82) compared with those in first complete remission; TNC <3 × 107/kg (HR 1.52, 95% CI 1.16-1.96, P = .011) and transplants between 2000 and 2004 (HR 1.52, 95% CI 1.23-1.85, P < .001) compared with transplants between 2005 and 2010.
Adjusted for patient age, disease, disease status, TNC, and transplant period: overall mortality risks were higher for patients >16 years compared with younger patients (HR 1.43, 95% CI 1.21-1.70, P < .001); acute lymphoblastic leukemia (HR 1.26, 95% CI 1.08-1.48, P = .004) compared with acute myeloid leukemia; mortality risks were lower for those with myelodysplastic syndrome (HR 0.65, 95% CI 0.50-0.84, P = .001) compared with acute myeloid leukemia; for those transplanted in relapse/refractory anemia with excess blasts (HR 2.98, 95% CI 2.44-3.64, P < .001) and in second complete remission (HR 1.51, 95% CI 1.21-1.88, P < .001) compared with those in first remission; TNC <3 × 107/kg (HR 1.37, 95% CI 1.14-1.67, P = .001) compared with TNC ≥3 × 107/kg and transplants between 2000 and 2004 (HR 1.35, 95% CI 1.18-1.56, P < .001) compared with transplants between 2005 and 2010.